BioMed X and Merck Collaboration Achieves Major Milestone

BioMed X Innovation Center and Merck announced that their collaboration, under which Merck has acquired all generated research and development results in the field of selective kinase inhibitors from BioMed X, reached a major milestone. In addition, the respective research group at BioMed X is now offering a unique set of bio- and cheminformatics services to research institutes and companies world-wide.
According to the press release:

BioMed X and Merck have jointly developed a unique innovation model which combines a global crowdsourcing approach with local incubation of the brightest ideas and research talents. Merck became the first partner of BioMed X in 2013. At the BioMed X Innovation Center on the life science campus of the University of Heidelberg, BioMed X and Merck jointly set up three new research groups. One of them, led by Simone Fulle, has developed novel bioinformatics tools that enable the design of highly selective inhibitors of kinases, a relatively large protein family which plays an important role in many human diseases such as cancer and chronic inflammation.

Click here to view the full press release.